EP2442785A1 - Agent for preventing or treating abnormality in skin water permeation function - Google Patents
Agent for preventing or treating abnormality in skin water permeation functionInfo
- Publication number
- EP2442785A1 EP2442785A1 EP10728911A EP10728911A EP2442785A1 EP 2442785 A1 EP2442785 A1 EP 2442785A1 EP 10728911 A EP10728911 A EP 10728911A EP 10728911 A EP10728911 A EP 10728911A EP 2442785 A1 EP2442785 A1 EP 2442785A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- skin
- nucleic acid
- purine nucleic
- water permeation
- tewl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 115
- 230000005856 abnormality Effects 0.000 title claims description 32
- 239000003795 chemical substances by application Substances 0.000 title description 58
- -1 Purine nucleic acid Chemical class 0.000 claims abstract description 73
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims abstract description 59
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 57
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 57
- 230000036572 transepidermal water loss Effects 0.000 claims description 104
- 230000002159 abnormal effect Effects 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 19
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 11
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 10
- 229960005305 adenosine Drugs 0.000 claims description 10
- 208000017520 skin disease Diseases 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 208000003251 Pruritus Diseases 0.000 claims description 8
- 206010040849 Skin fissures Diseases 0.000 claims description 8
- 206010048222 Xerosis Diseases 0.000 claims description 8
- 230000007803 itching Effects 0.000 claims description 8
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 7
- 230000032683 aging Effects 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 235000021317 phosphate Nutrition 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 20
- 239000004480 active ingredient Substances 0.000 abstract description 8
- 230000033228 biological regulation Effects 0.000 abstract description 6
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 239000003623 enhancer Substances 0.000 abstract 2
- 210000003491 skin Anatomy 0.000 description 174
- 230000006870 function Effects 0.000 description 60
- 238000012360 testing method Methods 0.000 description 59
- 210000000434 stratum corneum Anatomy 0.000 description 28
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 26
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 26
- 229950006790 adenosine phosphate Drugs 0.000 description 25
- 239000000523 sample Substances 0.000 description 23
- 239000000243 solution Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 8
- 210000002510 keratinocyte Anatomy 0.000 description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000013074 reference sample Substances 0.000 description 7
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical class C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- FYWLYWMEGHCZAX-MCDZGGTQSA-M sodium [(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate Chemical compound [Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)([O-])=O)[C@@H](O)[C@H]1O FYWLYWMEGHCZAX-MCDZGGTQSA-M 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical class CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- LNQVTSROQXJCDD-KQYNXXCUSA-N 3'-AMP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H]1O LNQVTSROQXJCDD-KQYNXXCUSA-N 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- QGWNDRXFNXRZMB-UUOKFMHZSA-N GDP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-N 0.000 description 1
- QGWNDRXFNXRZMB-UUOKFMHZSA-K GDP(3-) Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-K 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical class CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- QDFHPFSBQFLLSW-UHFFFAOYSA-N UNPD78433 Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1OP(O)(O)=O QDFHPFSBQFLLSW-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- QDFHPFSBQFLLSW-KQYNXXCUSA-N adenosine 2'-phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1OP(O)(O)=O QDFHPFSBQFLLSW-KQYNXXCUSA-N 0.000 description 1
- 229960001456 adenosine triphosphate Drugs 0.000 description 1
- OFBHPPMPBOJXRT-UHFFFAOYSA-N adenylosuccinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C2=NC=NC(NC(CC(O)=O)C(O)=O)=C2N=C1 OFBHPPMPBOJXRT-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- ZDPUTNZENXVHJC-UHFFFAOYSA-N cumingianoside D Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(OP(O)(O)=O)C1O ZDPUTNZENXVHJC-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical class CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZDPUTNZENXVHJC-UUOKFMHZSA-N guanosine 3'-monophosphate Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H]1O ZDPUTNZENXVHJC-UUOKFMHZSA-N 0.000 description 1
- 235000013928 guanylic acid Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229940028843 inosinic acid Drugs 0.000 description 1
- 235000013902 inosinic acid Nutrition 0.000 description 1
- 239000004245 inosinic acid Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- FRQONEWDWWHIPM-UHFFFAOYSA-N n,n-dicyclohexylcyclohexanamine Chemical class C1CCCCC1N(C1CCCCC1)C1CCCCC1 FRQONEWDWWHIPM-UHFFFAOYSA-N 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000008491 skin homeostasis Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008400 supply water Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the present invention relates to an agent for preventing or treating an abnormality in skin water permeation function.
- the present invention further relates to an agent for adjusting TEWL (transepidermal water loss) value, the amount of water evaporated from the skin, to normal levels.
- the present invention relates to a method for preventing or treating an abnormality in skin water permeation function, for adjusting TEWL value, for preventing or treating abnormal TEWL in skin, or for improving skin water permeation function/ and uses thereof.
- the skin plays several roles.
- the principal roles of the skin are providing protection from UV rays, foreign substances, microorganisms, etc., and providing water content adjustment function of the outermost skin layer, which contribute to skin homeostasis.
- the skin normally has an appropriate level of elasticity, flexibility, and strength, and can protect itself against physical force. However, for this ability to function, the skin must contain an appropriate amount of water, and be flexible.
- the outer skin layer contains natural moisturizing factors (NMF) and ceramides, whose combined effects enable the entire skin to maintain an appropriate water content and keep the skin flexible.
- NMF moisturizing factors
- moisture retention involves the suppression of the TEWL value and the inhibition of water permeation through the skin to thereby control water evaporation from the skin.
- the human skin has portions that are susceptible to dryness, eczema, or the like. Each skin site has different properties. However, it is difficult to selectively use, according to the skin site, a preparation that is effective for increasing or reducing the TEWL value. Therefore, the development of a single preparation that can both increase and decrease the TEWL value according to the skin site to adjust the TEWL value to an appropriate level has long been desired.
- purine nucleic acid has an effect of appropriately adjusting TEWL value according to the skin condition. More specifically, the inventors found that purine nucleic acid can increase TEWL value to normal levels when the skin has reduced TEWL, and can also decrease TEWL to normal levels when the skin has excessive TEWL; accordingly, purine nucleic acid can prevent or treat an abnormality in skin water permeation function.
- the present invention provides an agent for preventing or treating an abnormality in skin water permeation function having the following features.
- Item 1-1 An agent for preventing or treating an abnormality in skin water permeation function comprising, at least one purine nucleic acid as an active ingredient.
- Item 1-2 The agent for preventing or treating an abnormality in skin water permeation function according to Item 1-1 wherein the at least one purine nucleic acid is selected from the group consisting of adenosine monophosphates and salts thereof.
- Item 1-3 The agent for preventing or treating an abnormality in skin water permeation function according to Item 1-1 containing the purine nucleic acid in an amount of 0.1 to 20 wt.%.
- Item 1-4 The agent for preventing or treating an abnormality in skin water permeation function according to Item 1-1 which is used to adjust TEWL (transepidermal water loss) value.
- Item 1-5 The agent for preventing or treating an abnormality in skin water permeation function according to Item 1-1 which is used to prevent or treat a skin condition or a skin disease with abnormal TEWL value.
- Item 1-6 The agent for preventing or treating an abnormality in skin water permeation function according to Item 1-1, wherein the abnormality in skin water permeation function is due to aging.
- Item 1-7 The agent for preventing or treating an abnormality in skin water permeation function according to Item 1-1 which is used to prevent or treat rough skin, itching, chapped skin, hyperkeratosis, or senile xerosis.
- Item 1-8 The agent for preventing or treating an abnormality in skin water permeation function according to Item 1-1 which is in the form of a cosmetic, or a pharmaceutical or quasi-drug for external application to the skin.
- Item 1-9 The agent for preventing or treating an abnormality in skin water permeation function according to Item 1-1 which is used for non-therapeutic purpose.
- Item 1-10 Use of at least one purine nucleic acid for manufacture of an external composition for preventing or treating an abnormality in skin water permeation function.
- Item 1-11 Use of at least one purine nucleic acid, in an external composition, for preventing or treating an abnormality in skin water permeation function.
- Item 1-12 A purine nucleic acid for preventing or treating an abnormality in skin water permeation function.
- the present invention provides an agent for adjusting TEWL (transepidermal water loss) value having the following features.
- Item 2-1 A agent for adjusting for TEWL (transepidermal water loss) value comprising t least one purine nucleic acid as an active ingredient.
- Item 2-2. The agent for adjusting TEWL value according to Item 2- 1 wherein the purine nucleic acid is selected from the group consisting of adenosine monophosphate and salts thereof.
- Item 2-3. The agent for adjusting TEWL value according to Item 2- 1 containing the purine nucleic acid in an amount of 0.1 to 20 wt. %.
- Item 2-4 The agent for adjusting TEWL value according to Item 2- 1 which is used to improve skin water permeation function.
- Item 2-7 The agent for adjusting TEWL value according to Item 2-
- Item 2-8 The agent for adjusting TEWL value according to Item 2-
- Item 2-9 Use of at least one purine nucleic acid for manufacture of an external composition for adjusting TEWL (transepidermal water loss) value.
- Item 2-11 Use of at least one purine nucleic acid, in an external composition, for adjusting TEWL (transepidermal water loss) value.
- Item 2-12 A purine nucleic acid for adjusting TEWL (transepidermal water loss) value.
- a method for adjusting TEWL (transepidermal water loss) value comprising administering at least one purine nucleic acid to a subject in need of adjusting TEWL (transepidermal water loss) value.
- the present invention also provides following agents, use of the compounds, and methods.
- Item 3-1 A agent for preventing or treating abnormal TEWL
- transepidermal water loss in skin comprising at least one purine nucleic acid as an active ingredient.
- Item 3-2 Use of at least one purine nucleic acid for manufacture of an external composition for preventing or treating abnormal
- TEWL transepidermal water loss
- Item 3-3 Use of at least one purine nucleic acid, in an external composition, for preventing or treating abnormal TEWL (transepidermal water loss) in skin.
- TEWL transepidermal water loss
- Item 3-4 A purine nucleic acid for preventing or treating abnormal TEWL (transepidermal water loss) in skin.
- Item 3-5 A method for preventing or treating abnormal TEWL (transepidermal water loss) in skin, comprising administering at least one purine nucleic acid to a subject in need of preventing or treating abnormal TEWL.
- TEWL transepidermal water loss
- Item 3-6 An agent for improving skin water permeation function comprising least one purine nucleic acid as an active ingredient.
- Item 3-7. Use of at least one purine nucleic acid for manufacture of an external composition for improving skin water permeation function.
- Item 3-8 Use of at least one purine nucleic acid, in an external composition, for improving skin water permeation function.
- Item 3-9. A purine nucleic acid for improving skin water permeation function.
- Item 3-10 A method of improving skin water permeation function, comprising administering at least one purine nucleic acid to a subject in need of restoring or maintaining skin water permeation function.
- TEWL value can be adjusted according to the skin condition to thereby normalize skin water permeation function, thus enhancing skin water content regulation effect.
- skin conditions and skin diseases with abnormal skin water permeability such as rough skin, itching, chapped skin, hyperkeratosis, and senile xerosis, can be prevented or treated.
- Fig. 1 shows the TEWL measurement results obtained in Test Example 3, indicating the changes in TEWL value at the skin site where a test sample containing AMP was applied and at the skin site where the test sample was not applied.
- Fig. 2 shows the stratum corneum water content measurement results obtained in Test Example 3, indicating the changes in over time at the AMP-containing test sample application skin site, and at the non-application skin site.
- Fig. 3a is a photograph of the skin surface condition of the non-application skin site, which was observed after 7 days from the start of the test in Test Example 3.
- Fig. 3b is a photograph of the skin surface condition of the test sample application skin site, which was observed after 7 days from the start of the test in Test Example 3.
- a mode for carrying out the invention will be described below.
- a feature of the agent for preventing or treating an abnormality in skin water permeation function of the present invention is containing at least one purine nucleic acid as an active ingredient.
- the agent for preventing or treating an abnormality in skin water permeation function of the present invention may be referred to as “the agent of the invention” .
- purine nucleic acid used as an active ingredient in the present invention, is a general term that includes purine per se, various purine derivatives having a purine nucleus as the skeleton, and salts thereof, purine nucleic acid as used herein are not particularly limited insofar as they are pharmaceutically or cosmetically acceptable.
- adenosine phosphates are preferable, and adenosine monophosphates, particularly adenosine 5' -monophosphate (AMP), are more preferable.
- AMP adenosine 5' -monophosphate
- These purine nucleic acids can be used singly, or in a combination of two or more. Salts used as the purine nucleic acid are not particularly limited insofar as they are pharmaceutically or cosmetically acceptable.
- salts examples include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as magnesium salts, calcium salts, and barium salts; basic amino acid salts such as arginine salts and lysine salts; ammonium salts such as ammonium salts and tricyclohexylammonium salts; various kinds of alkanolamine salts such as monoethanolamine salts, diethanolamine salts, triethanolamine salts, monoisopropanolamine salts, diisopropanolamine salts, and triisopropanolamine salts; etc.
- alkali metal salts such as sodium salts and potassium salts
- alkaline earth metal salts such as magnesium salts, calcium salts, and barium salts
- basic amino acid salts such as arginine salts and lysine salts
- ammonium salts such as ammonium salts and tricyclohexylammonium salts
- alkali metal salts are preferable, and sodium salts are particularly preferable.
- the agent of the invention is applied to the skin to improve the water permeation function of the stratum corneum, and enhance skin water content regulation effect. Accordingly, the agent of the invention is provided as an external composition (an external preparation) , such as a cosmetic, or a pharmaceutical or quasi-drug for external application to the skin, which is used to prevent or treat an abnormality in skin water permeation function, or adjust TEWL value.
- an external composition such as a cosmetic, or a pharmaceutical or quasi-drug for external application to the skin, which is used to prevent or treat an abnormality in skin water permeation function, or adjust TEWL value.
- the amount of the purine nucleic acid in the external composition can be suitably selected according to the form of the preparation, application site, desired effect, etc. More specifically, the amount of the purine nucleic acid in the external composition is 0.1 to 20 wt.%, preferably 0.5 to 10 wt.%, and more preferably 1 to 5 wt.%, based on the total amount of the external composition.
- the external composition which contains a purine nucleic acid in the above-mentioned proportion, can exhibit a TEWL adjustment effect etc.
- the purine nucleic acid may be formulated with various optional components that are typically used in preparations for external application to the skin, such as pharmaceutically or cosmetically acceptable carriers and additives. Such carriers and additives are known in the art, and amounts thereof can be suitably selected.
- pH and osmotic pressure of the external composition can be suitably selected from the range that does not adversely affect low irritation to the skin or mucosa, and good skin feel upon application.
- the form of the external composition is not particularly limited, insofar as it is in a form externally applicable to the skin, such as a cosmetic, or pharmaceutical or quasi-drug for external application to the skin.
- the agent of the invention can be provided as an external preparation in the form of a paste, mousse, gel, liquid, emulsion, suspension, cream, ointment, sheet, aerosol, spray, liniment, or like desired forms, by adding the above-mentioned optional components and further optionally adding other solvents, and bases or carriers that are typically used in external preparations.
- liquids, emulsions, suspensions, and creams are preferable, and liquids and emulsions are particularly preferable.
- These products can be prepared by methods commonly used in the art.
- the agent of the invention is used to apply to the skin of a mammal (including a human) having an abnormality in skin water permeation function.
- the abnormality in skin water permeation function include skin diseases and skin conditions with excess TEWL value or reduced TEWL value.
- Specific examples of the abnormality in skin water permeation function include rough skin, itching, chapped skin, hyperkeratosis, senile xerosis, etc.
- preferable examples of the abnormality in skin water permeation function include that caused by aging.
- TEWL values reference can be made to Hachiro Tagami, "Kousho-kaishi (Journal of Cosmetic Science)" 27 (2003): 158.
- the agent of the invention can be used to apply to the target skin of a mammal (including a human) in need of restoring or maintaining TEWL value at normal levels, preventing or treating abnormal TEWL in skin, restoring or maintaining skin water permeation function, or adjusting TEWL value ability.
- the agent of the invention can prevent or treat an abnormal skin water permeation function.
- the agent of the invention can normalize the skin water permeation function in mammals such as humans by adjusting TWEL value to normal levels. Therefore, the agent of the invention can be used for providing a skin moisturizing effect and a skin water penetration enhancement effect, or regulating or restoring skin water content. More specifically, when applied to the skin with reduced TEWL value, the agent of the invention increases TEWL to thereby restore TEWL value to normal levels. When applied to the skin with excess TEWL value, the agent of the invention reduces TEWL value to thereby restore TEWL value to normal levels. Therefore, the agent of the invention is effective to prevent or treat skin conditions and skin diseases with abnormal TEWL value.
- the agent of the invention is effective for preventing or treating skin diseases and skin conditions (such as dry skin, itching, chapped skin, hyperkeratosis, and senile xerosis) with reduced TEWL value.
- the agent of the invention is also effective for preventing or treating skin diseases and skin conditions (such as rough skin) with excess TEWL value.
- the agent of the invention can adjust the skin with an excessive water content to an appropriate level, and can also restore the skin with a low water content to an appropriate level. Therefore, the agent of the invention is also effective for restoring deteriorated water retention ability.
- the agent of the invention may be applied in an appropriate amount to the skin once to several times per day according to the kind and concentration of the active ingredient, the user's age, sex, severity of skin condition, application form, desired effect, etc.
- the dose of the agent of the invention is such that the amount of the purine nucleic acid applied per application is 0.0001 to 1 mg, and preferably about 0.001 to about 1 mg, per cm 2 of the skin.
- the agent of the invention can adjust TEWL value to normal levels to thereby maintain skin water content at appropriate levels and appropriately evaporate water from the epidermis, thus appropriately adjusting TEWL value ability. Therefore, the agent of the invention can be used as an agent for improving skin water permeation function or an agent for adjusting TEWL value ability.
- the agent of the invention can normalize TEWL value in the skin. Therefore, the agent of the invention can be used as an agent for preventing or treating abnormal TEWL (transepidermal water loss) in skin.
- Test Example 1 Examination 1 of skin water permeation-promoting effect of adenosine phosphate
- 12 healthy human adults (10 males and 2 females; average age: 41.2 years old) were used as subjects. More specifically, 9 cm x 8 cm areas of the upper front right and left arms were used as test sites.
- An appropriate amount of a 20% hydrous ethanol solution containing 3% adenosine 5' -sodium monophosphate (AMP) (test sample) was applied to a test site on one arm, whereas the same amount of a 20% hydrous ethanol solution not containing AMP (reference sample) was applied to a test site on the other arm.
- the application was performed twice per day (in the morning and in the evening) for 28 days.
- the TEWL and the water content of the stratum corneum were measured before application (i.e., before the test) and after application (i.e., after 28 days of application) .
- the TEWL value (g/m 2 /h) was measured by using a DermaLab tester (manufactured by Cortex Technology) according to the instructions included with the DermaLab tester (manufactured by Cortex Technology) .
- the average TEWL value of each subject was calculated.
- the electric conductivity ( ⁇ S) was measured by using a SKICON-200 tester (manufactured by I. B. S Co., Ltd.) according to the instructions included with the SKICON-200 tester (manufactured by I. B. S Co., Ltd.), and used as an index for the water content of the stratum corneum.
- Table 1 shows the TEWL measurement results. Table 1 shows that when the reference sample was applied, there was substantially no difference between the TEWL values before and after the test; in contrast, when the test sample was applied, a tendency toward TEWL value increase was observed after 28 days of application, thus confirming enhanced skin water permeation function. Table 1
- Table 2 shows the stratum corneum water content measurement results. Table 2 shows that when the test sample was applied, a remarkable increase in the water content of the stratum corneum was observed after 28 days of application. Increased TEWL is generally considered to reduce the water content of the stratum corneum. However, the above test results revealed that AMP can increase both TEWL and the water content of the stratum corneum. Table 2
- test Example 1 a test was performed in a manner similar to Test Example 1, using an emulsion, which is generally used as an external cosmetic, in place of the aqueous ethanol solution used in Test Example 1.
- the test conditions such as the subject and the test period, were the same as in Test Example 1, except for the medium of the test sample and the test sites in the upper front arms.
- the emulsion used in this test has a general composition.
- cornified envelope (CE) in the stratum corneum was observed to investigate whether application of AMP affects skin barrier function. More specifically, to confirm the effect of application of AMP on the number of immature keratinocytes, tape was applied to the test sites so as to obtain the stratum corneum after 28 days of application of the test sample or the reference sample. The stratum corneum thus obtained was stained with a fluorescent-labeled anti-involucrin antibody, and mature keratinocytes were then stained with a fluorescent-labeled anti- mature cell antibody. Subsequently, each stained sample was observed under a fluorescence microscope to calculate the ratio of the number of immature keratinocytes to the total number of keratinocytes .
- Table 3 shows the TEWL measurement results. Table 3 shows that when the reference sample was applied, there was substantially no difference between the TEWL values before and after the test; in contrast, when the test sample was applied, a significant increase in TEWL was observed after 28 days of application, thus confirming enhanced skin water permeation function. Table 3
- Table 4 shows the stratum corneum water content measurement results. Table 4 shows that when the reference sample was applied, an increase in the water content of the stratum corneum was observed; when the test sample was applied, a more remarkable increase was observed.
- the increased water content of the stratum corneum achieved by application of the reference sample is believed to be due to a so-called temporal stratum corneum water retention effect obtained by coating the skin with a film.
- the increased water content of the stratum corneum and enhanced water permeation function achieved by application of the test sample are believed to result from enhanced stratum corneum function and increased ability to supply water from the deep layers of the skin to the outermost layer. Since these effects are provided by iraproving the skin' s own function and ability, the effects are expected to persist even after application of the test sample is completed.
- Table 5 shows the ratio of the number of immature keratinocytes to the total number of keratinocytes. It is generally believed that the observation of many immature keratinocytes in the stratum corneum indicates rough skin or reduced stratum corneum barrier function. As shown in Table 5, the results show that when the test sample containing AMP was applied, the ratio of the number of immature keratinocytes did not increase. Thus, the results confirmed that application of the test sample containing AMP does not reduce the skin barrier function.
- Test Example 3 Examination of skin water permeation-inhibitory effect of adenosine phosphate
- a test was conducted to examine the effect of an adenosine phosphate on a skin with overly enhanced skin water permeation function.
- the test was conducted using 9 healthy human adults (9 males; average age: 43.1 years old) as subjects. More specifically, 7 cm x 4.5 cm areas on the outer right and left calves of each subject were used as test sites.
- a 0.25 w/v% aqueous solution of sodium dodecyl sulfate (aqueous SDS solution, manufactured by Wako Pure Chemical Industries) was applied to the test sites on both the right and left calves in such a manner as to cover the test sites with an occlusive barrier for 24 hours.
- the application sites were washed and used as rough skin models.
- An emulsion containing 3% sodium adenosine 5' -monophosphate was used as a test sample.
- An appropriate amount of the emulsion containing sodium adenosine 5' -monophosphate was applied to a test site on one calf, whereas nothing was applied to a test site on the other calf.
- the application of the emulsion was started after the treatment with the aqueous SDS solution (day 0) , and was performed twice per day for 7 days.
- TEWL value and the stratum corneum water content were measured in the same manner as in Test Example 1, before and after treatment with the aqueous SDS solution; and after 1 day, 3 days, and 7 days of application of the test sample. Further, the surface condition of the skin after 7 days of application of the test sample was observed. The condition of the skin surface was observed using a microscope (manufactured by Scalar) .
- Fig. 1 shows the TEWL measurement results. As shown in
- Fig. 1 the treatment with the aqueous SDS solution clearly increased TEWL value, and also caused unmistakably rough skin; afterward, TEWL value was more sharply reduced at the test sample application skin site than at the non-application skin site according to observations after 3 days and 7 days of application.
- Fig. 2 shows the water content of the stratum corneum. As shown in Fig. 2, the treatment with the aqueous SDS solution obviously reduced the water content of the stratum corneum; afterward, the water content of the stratum corneum did not increase at the non-application skin site even after 7 days, whereas the water content of the stratum corneum was remarkably increased at the skin site where the test sample was applied.
- Figs. 3a and 3b show the skin surface condition observation results.
- the skin surface pattern composed of sulcus cutis, cristae cutis, and area cutanea, disappeared, and flaking of the stratum corneum was observed.
- the AMP-containing test sample application site Fig. 3b
- a skin surface pattern was observed, and no flaking of the stratum corneum was observed. The above results confirmed that application of the AMP-containing test sample is effective for ameliorating rough skin caused by excessive TEVJL value.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009146051 | 2009-06-19 | ||
| PCT/JP2010/060796 WO2010147238A1 (en) | 2009-06-19 | 2010-06-18 | Agent for preventing or treating abnormality in skin water permeation function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP2442785A1 true EP2442785A1 (en) | 2012-04-25 |
Family
ID=42752972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP10728911A Withdrawn EP2442785A1 (en) | 2009-06-19 | 2010-06-18 | Agent for preventing or treating abnormality in skin water permeation function |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2442785A1 (enExample) |
| JP (1) | JP2012530683A (enExample) |
| KR (1) | KR20120032009A (enExample) |
| CN (1) | CN102458351B (enExample) |
| WO (1) | WO2010147238A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2823807B1 (en) * | 2012-03-05 | 2021-03-17 | Otsuka Pharmaceutical Co., Ltd. | Sunscreen composition |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2844103B2 (ja) * | 1990-02-09 | 1999-01-06 | 株式会社コーセー | 皮膚外用剤 |
| JP3413220B2 (ja) * | 1992-08-17 | 2003-06-03 | 株式会社コーセー | 肌荒れ改善剤 |
| JP3172599B2 (ja) * | 1992-10-16 | 2001-06-04 | 株式会社コーセー | 細胞賦活剤 |
| JP3578858B2 (ja) * | 1995-12-11 | 2004-10-20 | 株式会社ノエビア | 皮膚外用剤 |
| JPH1129457A (ja) * | 1997-07-04 | 1999-02-02 | Kanebo Ltd | 皮膚化粧料 |
| WO1999055302A1 (en) * | 1998-04-27 | 1999-11-04 | Color Access, Inc. | Composition and method for treatment of aging skin |
| JP4164683B2 (ja) * | 2000-11-22 | 2008-10-15 | 大塚製薬株式会社 | Ｏ／ｗ型乳化組成物及びその調製方法 |
| JP2003206224A (ja) * | 2002-01-08 | 2003-07-22 | Otsuka Pharmaceut Co Ltd | 外用組成物 |
| JP4627988B2 (ja) * | 2002-04-09 | 2011-02-09 | 大塚製薬株式会社 | 細胞増殖用組成物 |
| JP4084726B2 (ja) * | 2003-09-30 | 2008-04-30 | 丸善製薬株式会社 | コラーゲン合成促進剤、線維芽細胞増殖促進剤、サイクリックａｍｐホスホジエステラーゼ阻害剤、チロシナーゼ阻害剤、及び血小板凝集抑制剤、並びに化粧料及び飲食品。 |
| JP2006225271A (ja) * | 2005-02-15 | 2006-08-31 | Otsuka Pharmaceut Co Ltd | シワの予防又は改善剤 |
| JP4980634B2 (ja) | 2006-03-17 | 2012-07-18 | ポーラ化成工業株式会社 | 肌荒れの予防、改善に好適な皮膚外用剤 |
| EP2174647B1 (en) * | 2007-08-06 | 2017-12-13 | Otsuka Pharmaceutical Co., Ltd. | Gel composition for external application containing an adenine compound |
| EP2238971B1 (en) * | 2008-01-11 | 2017-09-27 | Otsuka Pharmaceutical Co., Ltd. | Composition for external application |
-
2010
- 2010-06-18 CN CN201080027081.4A patent/CN102458351B/zh not_active Expired - Fee Related
- 2010-06-18 JP JP2011553179A patent/JP2012530683A/ja active Pending
- 2010-06-18 EP EP10728911A patent/EP2442785A1/en not_active Withdrawn
- 2010-06-18 WO PCT/JP2010/060796 patent/WO2010147238A1/en not_active Ceased
- 2010-06-18 KR KR1020127001387A patent/KR20120032009A/ko not_active Withdrawn
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2010147238A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1166705A1 (en) | 2012-11-09 |
| WO2010147238A1 (en) | 2010-12-23 |
| JP2012530683A (ja) | 2012-12-06 |
| KR20120032009A (ko) | 2012-04-04 |
| CN102458351B (zh) | 2014-04-16 |
| CN102458351A (zh) | 2012-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0715852B1 (en) | Use of hyaluronic acid or its salt to treat skin disease | |
| EP1547577B1 (en) | Antiaging composition | |
| JP7300988B2 (ja) | 外用組成物 | |
| CN107753332B (zh) | 一种多效油膏 | |
| Iizuka et al. | Adenosine and adenine nucleotides stimulation of skin (epidermal) adenylate cyclase | |
| JP2018531991A (ja) | 局所用抗ウイルス組成物 | |
| JP2006524038A5 (enExample) | ||
| US20160243011A1 (en) | Formulations Comprising Idebenone, N-Acetyl-S-Farnesyl-L-Cysteine and Ergothioneine and Uses Thereof | |
| CN103108640B (zh) | 包含烟酸腺嘌呤二核苷酸磷酸或该烟酸腺嘌呤二核苷酸磷酸的衍生物的药学或者化妆料组合物 | |
| CZ20001920A3 (cs) | Použití směsi diolu a alfa-hydroxykyseliny pro léčbu hyperkeratózních kožních onemocnění | |
| JP5546253B2 (ja) | 外用組成物 | |
| US9125928B2 (en) | Agent for suppressing the formation of abnormal skin cells caused by exposure to light | |
| DE19918750A1 (de) | Wirkstoffe, kosmetische und dermatologische Zubereitungen für die Verbesserung der Barrierefunktion | |
| WO2010147238A1 (en) | Agent for preventing or treating abnormality in skin water permeation function | |
| HK1166705B (en) | Agent for preventing or treating abnormality in skin water permeation function | |
| KR20160034371A (ko) | 말바 네글렉타 추출물을 사용하여 피부 장벽을 치료하고 여드름을 감소시키는 방법 | |
| JP2006298796A (ja) | 小じわ改善用皮膚外用剤 | |
| JP5846735B2 (ja) | 紅斑又は浮腫の改善剤 | |
| JP6038246B2 (ja) | 紅斑又は浮腫の改善剤 | |
| JP2006321778A (ja) | 皮膚修復用組成物及びそれを用いた皮膚修復剤 | |
| KR20240174630A (ko) | 포피라 334를 유효성분으로 포함하는 피부장벽강화, 가려움증 개선 또는 피부 상태 개선용 조성물 | |
| WO2008134033A1 (en) | Dna polymerase inhibitors composition and methods | |
| JP2004059440A (ja) | 肌荒れ防止および粘膜修復剤 | |
| HK1147698B (zh) | 外用组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20111220 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| 18W | Application withdrawn |
Effective date: 20141009 |